Omeros Corp
Open
Sector Healthcare
4.23 4.44
Overview
Share price change
24h
Min
3.99
Max
4.26
Income | -56M |
|---|---|
EPS | -0.15 |
Next Earnings | 7 lis 2024 |
|---|
Market Cap | -9.5M 216M |
|---|---|
Previous open | -0.21 |
Previous close | 4.23 |
News Sentiment
By Acuity
58%
42%
313 / 390 Ranking in Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Omeros Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Omeros Corp Forecast
Sentiment
By Acuity
313 / 390 Ranking in Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Omeros Corp
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its lead drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens replacement for adult and pediatric patients. Its drug candidate narsoplimab is the subject of a biologics license application (BLA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). It also has multiple Phase III and Phase II clinical-stage development programs in its pipeline, which are focused on complement-mediated disorders, including immunoglobulin A (IgA) nephropathy, atypical hemolytic uremic syndrome (aHUS) and COVID-19.
